Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema

被引:8
|
作者
Abdel-Hay, Ahmed [1 ,2 ]
Sivaprasad, Sobha [3 ]
Subramanian, Ahalya [1 ]
Barbur, John L. [1 ]
机构
[1] City Univ London, Appl Vis Res Ctr, London, England
[2] Musgrove Pk Hosp, Taunton, Somerset, England
[3] Moorfields Eye Hosp, London, England
来源
PLOS ONE | 2018年 / 13卷 / 06期
关键词
CHROMATIC SENSITIVITY; NEURAL APOPTOSIS; CLASSIFICATION; TRIAMCINOLONE; RETINOPATHY; PREVALENCE; PATHWAYS; HYPOXIA; SYSTEM;
D O I
10.1371/journal.pone.0199693
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose To evaluate changes in colour vision following intravitreal injection of Dexamethasone implant (Ozurdex) in patients with diabetic macular oedema (DMO). Both red-green (RG) and yellow-blue (YB) chromatic sensitivity were assessed using the Colour Assessment & Diagnosis (CAD) test which isolates the use of colour signals and provides age-corrected, statistical limits for normal trichromats. To determine whether colour changes and visual acuity (VA) post-treatment relate to central sub-field retinal thickness (CST). Methods Fourteen patients with DMO who were undergoing treatment with Ozurdex were recruited for this study. RG and YB colour thresholds were measured using the CAD test, best corrected visual acuity was assessed using the ETDRS chart and CST was measured using spectral domain optical coherence tomography (SD-OCT). All tests were performed monocularly at baseline and 24 weeks post injection. Results All patients (n = 14 eyes), had significant loss of RG and YB chromatic sensitivity at baseline (p<0.05). The mean age was 56 +/- 9.5 years. The age specific, monocular, upper normal limits for a 56 year old subject are 2.66 for RG and 2.85 for YB. In this study, the measured, pre injection thresholds (mean +/- SD) were 22.6 +/- 11.3 for RG and 16.2 +/- 3.76 for YB. There was significant improvement in RG threshold post injection (i.e., 19.2 +/- 10.8 (p<0.05)). No significant changes were found in the YB thresholds with corresponding mean and range values of: 15.8 +/- 4.6 (p = 0.23). CST pre-treatment was 542 +/- 135 mu m. After treatment and by week 24 the CST values decreased to 435 +/- 127 mu m. Conclusions RG colour thresholds provide a sensitive measure of functional change in diabetic subjects with macular oedema. The YB system is damaged severely in the DMO patients studied and shows little or no recovery post treatment. The improvement in VA and particularly in RG colour vision correlate well with the measured decrease in CST. The results suggest that the improvement in the RG chromatic sensitivity can provide a useful biomarker for monitoring the efficacy of treatment in DMO.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] AN AUDIT OF THE SAFETY AND EFFICACY OF THE DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX) IN IRISH PATIENTS WITH MACULAR OEDEMA
    Kennelly, Kevin
    Keegan, David
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 116 - 116
  • [32] Dexamethasone intravitreal implant in the treatment of diabetic macular edema
    Dugel, Pravin U.
    Bandello, Francesco
    Loewenstein, Anat
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 1321 - 1335
  • [33] Efficacy of dexamethasone intravitreal implant in diabetic macular edema
    Bonnin, Sophie
    Dupas, Benedicte
    Perol, Julien
    Erginay, Ali
    Tadayoni, Ramin
    Massin, Pascale
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [34] Intravitreal Dexamethasone Implant for Persistent Diabetic Macular Edema
    Alagoz, Cengiz
    Gunes, Hasan
    Baz, Okkes
    Yuksel, Kemal
    Yilmaz, Ihsan
    Yazici, Ahmet Taylan
    Demirok, Ahmet
    OPHTHALMOLOGICA, 2014, 232 : 18 - 18
  • [35] Fluocinolone Acetonide Intravitreal Implant (Iluvien®)In Diabetic Macular Oedema
    Mark Sanford
    Drugs, 2013, 73 : 187 - 193
  • [36] Early Retinal and Choroidal Coat Thickness Changes after Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema
    Horozoglu, Fatih
    Sever, Ozkan
    BALKAN MEDICAL JOURNAL, 2018, 35 (05) : 384 - 387
  • [37] Fluocinolone Acetonide Intravitreal Implant (Iluvien®) In Diabetic Macular Oedema
    Sanford, Mark
    DRUGS, 2013, 73 (02) : 187 - 193
  • [38] Safety and efficacy of Dexamethasone intravitreal implant (Ozurdex®) for the treatment of diabetic macular oedema in pseudophakic patients. The Portsmouth experience
    Sepetis, Anastasios
    Tsokolas, Georgios
    Mourtzoukos, Spyridon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [39] Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) in Diabetic Macular Oedema: A Case Series study.
    Bedan, Aseel Hamoud
    Palmieri, Filomena
    Hassan, Islam
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [40] Real world effectiveness of intravitreal injection of ranibizumab in patients with diabetic macular oedema
    Rashad, M.
    Meyer-Bothling, U.
    EYE, 2017, 31 : S11 - S13